Chief Executive Officer

Professor Amit Nathwani

Professor Amit Nathwani is the founder of NovalGen and serves as the Company’s CEO and is a member of the Board of Directors. Professor Nathwani is a renowned serial innovator and entrepreneur. He has an international reputation for his work in cancer research, immunology, and gene therapy and has been the recipient of a number of awards, including Outstanding Achievement Award in 2016 from ESGCT and American Society of Hematology and the Ham-Wasserman Lecture award in 2019. He is well known for his dedication to translational medicine and his commonly cited pioneering work in gene therapy where he was the first to show successful correction of bleeding diathesis in patients with severe hemophilia B.

He is the Founder and was the CSO (until end 2020) and now serves as a Board member of Freeline. Over the last 20 years Professor Nathwani has coordinated numerous Phase II and III trials in the treatment of refractory chronic lymphocytic leukaemia and is an author of more than 200 publications. He is the Principal Investigator on several early phase studies and an author of several patents. He continues to serve as the Director of the Katharine Dormandy Hemophilia Centre at the Royal Free Hospital and as a Senior NIHR Investigator. Additionally, he has also been a Professor of Hematology at University College London since November 2011. Prof. Nathwani graduated with MBChB from the University of Aberdeen in 1984 and is a fellow of the Royal College of Physician as well as the Royal College of Pathologist since June 1995. He holds a PhD in Molecular Biology.

Chief Scientific Officer

Professor Kerry Chester

Professor Kerry Chester is a renowned Professor of Molecular Medicine with over 25 years’ experience in antibody engineering and phage-display technology and has been named one of the top 50 Global Antibody Industry Influencers by The European Antibody Congress. Professor Chester created and led the first phage-derived single chain Fv antibody used in human trials and she has subsequently led development of novel antibodies used as cancer imaging agents, recombinant antibody-enzyme fusion proteins, antibody drug conjugates and chimeric antigen receptors.

She is on the Board of Directors of The Antibody Society and on the advisory board for major international meetings. Professor Chester obtained her PhD from the University of London where she studied human antibody responses to cancer and she furthered developed phage technology in Sir Greg Winter’s laboratory at Cambridge.

Chief Operating Officer

Nilesh Modi

Nilesh Modi is a seasoned strategy and operations executive with over 20 years’ leadership experience working for top strategic research and advisory firms and spearheading the growth of start-ups to Fortune 500 companies. He led transformation and growth initiatives for globally leading companies, such as Apple, HSBC, Microsoft, FedEx, and HP among others.

Most recently, as part of the senior leadership team, he drove eBay’s mobile enterprise strategy, operations, and marketing to expand eBay’s share and optimise its multi-platform infrastructure which was instrumental in the company’s mobile business growth from $8BN to $20BN. He received a B.S. in Business Management from Webster University in St. Louis and an M.A. in Research & Marketing with honours from Southern Illinois University in Edwardsville.

Chief Business Officer

Dr Natalia Misciattelli

Dr Natalia Misciattelli is an experienced life sciences executive with over 20 years’ industry experience. She previously served as Senior Vice President, Strategy and Business Operations for Freeline from the preclinical stage through to completion of a successful US Nasdaq listing. Prior to Freeline, Dr Misciattelli worked in the life sciences sector as a partner at PA Consulting running strategy and operational transformation programs for life sciences clients globally.

She has broad strategic and operational experience, spanning corporate to product strategies and broad operational experience from negotiating large sourcing contracts, to setting up new business units, as well as designing operating models for top-tier multinational pharmaceutical companies, including Pfizer, Novartis, and Johnson & Johnson. Prior to that, she was in Corporate Development & Strategy at General Electric Healthcare having started her career in Finance at Arthur Andersen in London. She received a B.Sc. and a Ph.D. in Marine Microbiology from Bangor University, University of Wales.

Dr Kieran O’Donovan

Dr Kieran O’Donovan has more than 25 years’ experience in the Biotech/Biopharma industry, starting his career heading up Research and Development in the then nascent probiotic industry before moving into the CMC arena at Protherics. At Protherics, he led process development working on Fab fragments and recombinant proteins. In 2007, he moved to Ipsen as Head of Industrialisation, becoming Vice President of Toxins and Biologics in 2011 developing natural and recombinant toxins as well as recombinant proteins for the treatment of Hemophilia. 

Dr O’Donovan later took up the role of Head of CMC at ReNeuron in 2015 and was promoted to Director of CMC in 2017 leading the development, manufacture and clinical supply of their allogenic stem cell therapies. He holds a PhD in computer modelling of a bioreactor process from the University of Surrey and is a microbiologist by training.

More in this section

Our history

Headquartered in London, UK, NovalGen was formed in 2019. The company is based on proprietary innovations from UCL, London UK.

Read more

Our investors

Find out more about our investors

Our investors